Inter-alpha-trypsin inhibitor as a marker for sepsis
AssigneeRhode Island Hospital
InventorsYow-Pin Lim, Douglas C. Hixson
Life of this patent
Estimating the term…
Abstract
The invention provides a method of diagnosing sepsis in a mammal by contacting a bodily fluid from the mammal with a ligand which binds to an inter-alpha trypsin inhibitor (ITI) polypeptide under conditions sufficient to form an ITI-ligand complex and detecting the complex.
Claims20
A method for diagnosis of sepsis in a mammal, comprising contacting a bodily fluid from said mammal with a monoclonal antibody which binds to bikunin, a bikunin-containing inter-alpha trypsin inhibitor (ITI) glycoprotein with an apparent molecular mass of 250 kDa and a bikunin-containing ITI glycoprotein with an apparent molecular mass of 125 kDa under conditions sufficient to form an immune complex and detecting the immune complex to determine an ITI level, wherein said bodily fluid is blood, serum, or plasma, and wherein a decrease in the level of ITI in a test sample compared to a normal level of ITI indicates a diagnosis of sepsis.
A method for prognosis of sepsis of a mammal, comprising contacting a bodily fluid from said mammal with a monoclonal antibody which binds to an bikunin, a bikunin-containing inter-alpha trypsin inhibitor (ITI) glycoprotein with an apparent molecular mass of 250 kDa, and a bikunin-containing ITI glycoprotein with an apparent molecular mass of 125 kDa under conditions sufficient to form an immune complex;
- quantitating the amount of complex to determine the level of ITI in said fluid;
- and comparing the level of ITI in said fluid over time, wherein said bodily fluid is blood, serum, or plasma, and wherein decreasing levels of ITI over time indicates an adverse prognosis.
A method for prognosis of sepsis, comprising contacting a bodily fluid from said mammal with a monoclonal antibody which binds to a bikunin-containing inter-alpha trypsin inhibitor (ITI) glycoprotein with an apparent molecular mass of 250 kDa and a bikunin-containing ITI glycoprotein with an apparent molecular mass of 125 kDa under conditions sufficient to form an immune complex and detecting the immune complex to determine an ITI level, wherein said bodily fluid is blood, serum, or plasma, and wherein an ITI level of 0.3 mg/ml or lower indicates a high risk of mortality.
Dependencies are inferred from the claim text.